-
Mashup Score: 1
AbstractBackground. Atorvastatin and sacubitril/valsartan (Entresto™) have been cornerstones in managing patients with coronary artery disease and heart failure
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease - 2 year(s) ago
Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate (eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). The
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
We discuss strategies to guide management of #HF #GDMT classes across #GFR ranges, and include #RCT evidence to support these recommendations. 1st and 2nd line #HFrEF drugs reviewed https://t.co/ye35TImVQM @HeartOTXHeartMD @BiykemB #SGLT2i #ARNI #RAASi #BB #cardiorenal https://t.co/yD4gVOe4gn
-
-
Mashup Score: 0Angiotensin‐Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure - 2 year(s) ago
Aims Patients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin/neprilysin in…
Source: Wiley Online LibraryCategories: Cardiologists, Latest HeadlinesTweet-
📌Angiotensin-Neprilysin Inhibition & Renal Outcomes across the Spectrum of Ejection Fraction in #HeartFailure https://t.co/ocIFjl7fLG #SacubitrilValsartan #ARNI #CardioEd #CardioTwitter https://t.co/QEZSmzXjF3
-
-
Mashup Score: 23Re-emergence of heart failure with a normal ejection fraction? - 2 year(s) ago
This editorial refers to ‘Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction’, by J. Butler et al.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Re-emergence of HF with a normal EF? in #EHJ by #Kondo & #McMurray. Do treatment effects of #SGLT2i attenuate at higher #LVEF similar to #ARB #ARNI #MRA & #digitalis? Stay tuned for #DELIVER in '22 evaluating dapa in 6,263 pts, incl 1,892 with LVEF≥60%. https://t.co/iiiYIECbrL https://t.co/3UrKrBXzto
-
-
Mashup Score: 1Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: - 2 year(s) ago
Abstract Objectives The authors sought to investigate associations between sacubitril/valsartan adherence and clinical outcomes after hospitalization for heart failure with reduced ejection fractio…
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients 🏥 for #HFrEF Patients with high adherence to Sa/Va after discharge from HF 🏥 have a lower adjusted risk of rehospitalization and ☠️ compared with patients with poor adherence https://t.co/78qh5wuIEi #ARNI https://t.co/enolSCLoBV
-
-
Mashup Score: 3Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure - 2 year(s) ago
This Viewpoint advocates for expanded use of quadruple therapy in patients with heart failure with reduced ejection fraction.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#SGLT2 inhibitor works just as well in terms of relative risk reduction for mortality and hospitalization whether the patient is on an #ARNI or not on an ARNI, whether they're on a beta-blocker or not on a beta-blocker https://t.co/30QmcwrLjp #ESCardioAsia #CVCT2021 @JavedButler1 https://t.co/SUmhHZegpD
-
-
Mashup Score: 14Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction - 3 year(s) ago
This randomized clinical trial evaluates the use of sacubitril/valsartan therapy compared with valsartan alone in US patients with advanced chronic heart failure.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#LIFE RCT #ARNI in #AdvancedHF #HFrEF An important effort of #Branwald et al severely impacted by the #Covid19 pandemic 🧩 Whereas no consideration can be drawn on the efficacy at least there are further safety signals of #ARNI https://t.co/AWMCuPHrOS @JAMACardio @DLBHATTMD https://t.co/nWeBFhYOYe
-
-
Mashup Score: 3
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients …
Categories: Cardiologists, Latest HeadlinesTweet-
Safety Events & Blood Pressure in #VICTORIA #Vericiguat was safe even in pts: 🍀>75 🍀SBP<110 mmHG 🍀On #ARNI ⬇️ 1st End-Point in Hypotensive Pts 🔥 @DrMarthaGulati @AnastasiaSMihai @JavedButler1 @DrNasrien @AHAScience @JBauersachsMD @DLBHATTMD @hvanspall https://t.co/bQVjDDPfly https://t.co/wLbRRWedDS https://t.co/E9yYqkq8io
-
-
Mashup Score: 34
Abstract. Chronic kidney disease (CKD) is highly prevalent in patients with chronic heart failure (CHF) and increases the risk of overall and cardiovascular (CV
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
👆 #RenalProtection of #ARNI in #HeartFailure @nephondemand @JavedButler1 @DrNasrien @gcfmd @JJheart_doc @HeartOTXHeartMD @markcpetrie20 @AnnaKateBarton @PSJhund @Dr_Manito @IC_LaFe @DrDEliaEmilia @novitskiynic @gabianfortes @DBelardoMD @MicheleSenni https://t.co/4sQW4y4fUf https://t.co/lLwTWGK5nH
-
#ARNI Renal protection in #HeartFailure Not only effect on Afferent & Efferent Arteriole but also direct effect on Podocyte/Mesangium & Antiinflammatory properties ✅ @AnastasiaSMihai @DrMarthaGulati @gbiondizoccai @mmamas1973 @DLBHATTMD @CNCFCardio https://t.co/4sQW4y4fUf https://t.co/t3GkQSkZ4q
-
-
Mashup Score: 5
The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 3 – Neutral Trials, A 2nd Chance, & A Paradigm Shift
Source: CardionerdsCategories: Expert Picks, Latest HeadlinesTweet-
3/ The Evolution of The Neurohormonal Hypothesis with Dr. Milton Packer ❤️🤓 Part 3: Neutral Trials, A 2nd Chance, & A Paradigm Shift ...the amazing story of #ARNI & beyond! @shirlywhirlmd @MarkBelkinMD @UCCardsFellows 🔗https://t.co/wkKyg0xUlC https://t.co/CqlkNN9CN1
-
Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and #ARNI: https://t.co/BqIpIiXpKo #EHJCaseReports @KardiologieHH @aayshacader @TJ_Yeo @ANazmiCalik @FarhanaAra @EHJCREiC https://t.co/8mptbZju8x